PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer ; volume:8 ; number:1 ; day:20 ; month:7 ; year:2022 ; pages:1-8 ; date:12.2022
npj Breast cancer ; 8, Heft 1 (20.7.2022), 1-8, 12.2022
- Urheber
-
Agostinetto, Elisa
Ameye, Lieveke
Martel, Samuel
Aftimos, Philippe
Pondé, Noam
Maurer, Christian
El-Abed, Sarra
Wang, Yingbo
Vicente, Malou
Chumsri, Saranya
Bliss, Judith
Kroep, Judith
Colleoni, Marco
Petrelli, Fausto
Mastro, Lucia Del
Moreno-Aspitia, Alvaro
Piccart, Martine
Paesmans, Marianne
Azambuja, Evandro de
Lambertini, Matteo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-022-00452-8
- URN
-
urn:nbn:de:101:1-2022100220014890582630
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:29 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Agostinetto, Elisa
- Ameye, Lieveke
- Martel, Samuel
- Aftimos, Philippe
- Pondé, Noam
- Maurer, Christian
- El-Abed, Sarra
- Wang, Yingbo
- Vicente, Malou
- Chumsri, Saranya
- Bliss, Judith
- Kroep, Judith
- Colleoni, Marco
- Petrelli, Fausto
- Mastro, Lucia Del
- Moreno-Aspitia, Alvaro
- Piccart, Martine
- Paesmans, Marianne
- Azambuja, Evandro de
- Lambertini, Matteo
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Predictive biological factors for late survival in patients with HER2-positive breast cancer
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
How We Treat HER2-Positive Metastatic Breast Cancer
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Predictive biological factors for late survival in patients with HER2-positive breast cancer
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
How We Treat HER2-Positive Metastatic Breast Cancer
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Predictive biological factors for late survival in patients with HER2-positive breast cancer
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients